Associate professor at Tongji university, China
Lingfei Han is a dedicated medical professional and accomplished researcher in the field of gynecological oncology. Currently serving as an attending surgeon and instructor at the Shanghai First Maternity and Infant Hospital affiliated with Tongji University School of Medicine, Han has cultivated a dual career in both clinical practice and biomedical research. With a strong foundation in clinical medicine and molecular biology, he has developed a specialized focus on cancer immunotherapy, tumor microenvironment, and immunoregulatory pathways relevant to cervical and ovarian cancers. His extensive experience in translational oncology has led to multiple impactful publications and research projects supported by national funding agencies.
Profile
Scopus
Education:
Lingfei Han pursued his medical education entirely at Tongji Medical College of Huazhong University of Science and Technology, where he earned his Bachelor of Medicine degree in Clinical Medicine in 2003. He subsequently deepened his understanding of disease mechanisms through a Master of Science degree in Molecular Biology, completed in 2006. Motivated by a growing interest in gynecologic malignancies, he undertook doctoral studies in Gynecological Oncology and obtained his Ph.D. in 2009. This academic trajectory provided a robust scientific and clinical foundation for his future career in oncologic surgery and immunotherapy research.
Experience:
Since July 2009, Han has been part of the OB/GYN Department at the Shanghai First Maternity and Infant Hospital, beginning his tenure as a resident surgeon and advancing to the position of attending surgeon. Over the years, he has developed proficiency in a range of surgical techniques and has been actively involved in the care and treatment of patients with gynecological cancers. Alongside his clinical responsibilities, he has served as an instructor, mentoring medical students and junior clinicians while continuously participating in laboratory-based cancer research projects.
Research Interest:
Han’s research primarily focuses on the immunological aspects of gynecological cancers, especially cervical and ovarian cancers. He has developed expertise in molecular and cell biology techniques, including recombinant adeno-associated virus construction, flow cytometry, and immunohistochemistry. His major research interests include the immune escape mechanisms in cancer via pathways such as BTLA-HVEM and PD-1/PD-L1 signaling, the development of in vivo tumor models, and cancer gene therapy strategies. Notably, his work includes the use of animal models to simulate metastatic progression and immune modulation, as well as the development of gene panels and nanomedicine platforms for targeted cancer therapy.
Awards:
Lingfei Han has been the recipient of several prestigious research grants and recognitions throughout his career. His notable funded projects include the study of soluble BTLA’s role in immune surveillance evasion in cervical cancer, supported by the Natural Science Foundation of China (2011–2013), and an investigation into its mechanisms in ovarian cancer, funded by the Youth Science and Technology Phosphorus Program of Shanghai. Additionally, his early career promise was acknowledged through Tongji University’s Youth Outstanding Personnel Training Plan grant for exploring BTLA-HVEM signaling in immune escape (2009–2011).
Publications:
Han has authored and co-authored numerous impactful scientific articles. Selected publications include:
- EIF4A3-regulated circ_0087429 reverses EMT in cervical cancer via miR-5003-3p/OGN axis, J Exp Clin Cancer Res, 2022 (Cited by over 40 articles).
- Myeloid-derived suppressor cells interact with B10 cells via BAFF/BAFF-R in cervical cancer, Cancer Immunol Immunother, 2022 (Cited by 30+).
- A Pyroptosis-Related Gene Panel in Cervical Cancer, Front Oncol, 2022 (Cited by 25).
- CMTM6 Overexpression in Ovarian Cancer Immune Infiltration, Front Mol Biosci, 2022 (Cited by 18).
- PLGA nanoparticles for co-delivery of drugs in ovarian cancer, Drug Des Devel Ther, 2019 (Cited by 35).
- CD163+ and CD68+ macrophages in HPV-related cervical cancer, J Cancer, 2017 (Cited by 50+).
- Soluble BTLA boosts HSP70 vaccine-induced tumor immunity, J Immunol, 2009 (Cited by 60+).
Conclusion:
Through a well-balanced integration of clinical care and innovative research, Lingfei Han has made substantial contributions to the understanding and treatment of gynecologic cancers. His work in immune modulation and cancer therapeutics not only advances scientific knowledge but also holds tangible benefits for clinical applications in oncology. His continuous efforts in mentoring, publishing, and research underscore a career committed to translational science and improving patient outcomes. Han’s trajectory demonstrates the importance of a rigorous academic background, interdisciplinary collaboration, and sustained inquiry into cancer immunology.